Nezastomig clinical trials
Also written REGN5678.
How each study uses nezastomig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nezastomig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
M.D. Anderson Cancer Center (2) · Regeneron Pharmaceuticals (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test nezastomig.
- May 2027A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPCPhase 1 · M.D. Anderson Cancer Center
- Nov 2027A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsPhase 1/2 · Regeneron Pharmaceuticals
Studies
Open first, then newest update. How each study uses nezastomig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03972657Written as REGN5678
- A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical ProstatectomyRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06085664Written as REGN5678
- A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPCRecruitingPhase 1M.D. Anderson Cancer CenterNCT06826768Written as REGN5678
Given beside what is tested · 2 — nezastomig is usual care or a partner of the new treatment
- REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsNot yet recruitingPhase 1/2Regeneron PharmaceuticalsNCT07850921Written as Nezastomig
- A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerRecruitingPhase 1/2Regeneron PharmaceuticalsNCT05125016Written as REGN5678
Codes
What other systems call nezastomig · ClinicalTrials.gg INT017235
- UNII (FDA) M355PGI1TGNEZASTOMIGOne source FDA
- NCI Thesaurus C162936NezastomigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M355PGI1TG | NEZASTOMIG | One source FDA |
| NCI Thesaurus | C162936 | Nezastomig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.